UNSPSC 51272702: Pramocaine or pramoxin or pramoxine

This classification denotes an anesthetic agent with the molecular formula C17H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 068X84E056, chemically known as morpholine, 4-(3-(p-butoxyphenoxy)propyl)- but generally known as pramocaine, which bears US NIH Compound Identifier 4886. European Medicines Agency schedules Pramocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09994MIG.

The term PRAMOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules pramocaine in its Anatomical Therapeutic Chemical (ATC) Classification. PRAMOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2.

UNSPSC 51272702 Pramocaine or pramoxin or pramoxine (Commodity) describes a local anesthetic pharmaceutical ingredient, but recent state and local procurement activity under this code shows minimal direct solicitation. The three most recent opportunities posted in the source span pharmaceutical procurement more broadly — naloxone systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals — yet none explicitly names pramocaine or pramoxine as a line item or product category. State and local buyers soliciting under this code appear to be county health departments, state health and human services commissions, and cooperative purchasing alliances; however, the source does not establish a pattern of sustained or focused activity targeting pramocaine specifically.

Geographic activity is sparse and dispersed. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) on direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. The code shows little recent relevant activity tied explicitly to pramocaine procurement; the broader pharmaceutical opportunities do not isolate this commodity as a target item.